A Novel Panel of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Alzheimer’s Disease versus Normal Aging and Frontotemporal Dementia

2007 ◽  
Vol 24 (6) ◽  
pp. 434-440 ◽  
Author(s):  
A.H. Simonsen ◽  
J. McGuire ◽  
V.N. Podust ◽  
N.-O. Hagnelius ◽  
T.K. Nilsson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Differential Diagnosis ◽  
Frontotemporal Dementia ◽  
Normal Aging ◽  
Cerebrospinal Fluid Biomarkers

Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers

2019 ◽  
Vol 72 ◽  
pp. 24-29
Author(s):  
Lucia Farotti ◽  
Federica Nicoletta Sepe ◽  
Andrea Toja ◽  
Roberta Rinaldi ◽  
Lucilla Parnetti
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Differential Diagnosis ◽  
Cerebrospinal Fluid Biomarkers

scholarly journals Improved Differential Diagnosis of Alzheimer’s Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers

2019 ◽  
Vol 67 (2) ◽  
pp. 639-651 ◽  
Author(s):  
Payam Emami Khoonsari ◽  
Ganna Shevchenko ◽  
Stephanie Herman ◽  
Julia Remnestål ◽  
Vilmantas Giedraitis ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Differential Diagnosis ◽  
Cerebrospinal Fluid Biomarkers

Definite Behavioral Variant of Frontotemporal Dementia with C9ORF72 Expansions Despite Positive Alzheimer's Disease Cerebrospinal Fluid Biomarkers

2012 ◽  
Vol 32 (1) ◽  
pp. 19-22 ◽  
Author(s):  
David Wallon ◽  
Anne Rovelet-Lecrux ◽  
Vincent Deramecourt ◽  
Jeremie Pariente ◽  
Sophie Auriacombe ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Frontotemporal Dementia ◽  
Cerebrospinal Fluid Biomarkers

scholarly journals Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease

2015 ◽  
Vol 51 (6) ◽  
Author(s):  
Carolina A. Magalhães ◽  
Micheli Figueiró ◽  
Vanessa G. Fraga ◽  
Elvis C. Mateo ◽  
André A. S. F. Toledo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Differential Diagnosis ◽  
Cerebrospinal Fluid Biomarkers

scholarly journals Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia

2015 ◽  
Vol 40 (1-2) ◽  
pp. 54-62 ◽  
Author(s):  
Nina Rostgaard ◽  
Gunhild Waldemar ◽  
Jørgen Erik Nielsen ◽  
Anja Hviid Simonsen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Frontotemporal Dementia ◽  
Core Protein ◽  
Tau Pathology ◽  
Protein Biomarkers ◽  
Cerebrospinal Fluid Biomarkers ◽  
Best Medical Treatment ◽  
New Biomarkers

As dementia is a fast-growing health care problem, it is becoming an increasingly urgent need to provide an early diagnosis in order to offer patients the best medical treatment and care. Validated biomarkers which reflect the pathology and disease progression are essential for diagnosis and are important when developing new therapies. Today, the core protein biomarkers amyloid-β42, total tau and phosphorylated tau in the cerebrospinal fluid (CSF) are used to diagnose Alzheimer's disease (AD), because these biomarkers have shown to reflect the underlying amyloid and tau pathology. However, the biomarkers have proved insufficient predictors of dementias with a different pathology, e.g. frontotemporal dementia (FTD); furthermore, the biomarkers are not useful for early AD diagnosis. Familial dementias with a known disease-causing mutation can be extremely valuable to study; yet the biomarker profiles in patients with familial dementias are not clear. This review summarizes CSF biomarker findings from studies on symptomatic and presymptomatic individuals carrying a mutation in one of the genes known to cause early-onset familial AD or FTD. In conclusion, the biomarker profile of inherited AD is quite similar between carriers of different mutations as well as similar to the profile found in sporadic AD, whereas familial FTD does not seem to have a clear biomarker profile. Hence, new biomarkers are needed for FTD.

Sign in / Sign up

Export Citation Format

Share Document